Pazopanib: The Newest Tyrosine Kinase Inhibitor for the Treatment of Advanced or Metastatic Renal Cell Carcinoma

By Keisner Sidney V.   Shah Sachin R.  

Drugs, Vol. 71, Iss. 4, 2011-03 ,pp. : 443-454

Adis International

Access to resources Recommend Favorite

Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor

By Marshall John L.   Kindler Hedy   Deeken John   Bhargava Pankaj   Vogelzang Nicholas J.   Rizvi Naiyer   Luhtala Taina   Boylan Stacy   Dordal Margaret   Robertson Philmore   Hawkins Michael J.   Ratain Mark J.  

Investigational New Drugs, Vol. 23, Iss. 1, 2005-01 ,pp. : 31-37

Springer Publishing Company

Access to resources Recommend Favorite

ZD6474, a Small Molecule Tyrosine Kinase Inhibitor, Potentiates the Anti-Tumor and Anti-Metastasis Effects of Radiation for Human Nasopharyngeal Carcinoma

By  

Current Cancer Drug Targets, Vol. 10, Iss. 6, 2010-01 ,pp. : 611-622

Bentham Science Publishers

Access to resources Recommend Favorite

A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy

By Garcia Jorge A.   Hudes Gary R.   Choueiri Toni K.   Stadler Walter M.   Wood Laura S.   Gurtler Jayne   Bhatia Shailender   Joshi Adarsh   Hozak Rebecca R.   Xu Yihuan   Schwartz Jonathan D.   Thompson John A.  

Cancer, Vol. 120, Iss. 11, 2014-06 ,pp. : 1647-1655

Blackwell Publishing

Access to resources Recommend Favorite

Gender Effects on Rat Metabolism of AMG 900, an Orally Available Small Molecule Aurora Kinase Inhibitor

By  

Drug Metabolism Letters, Vol. 5, Iss. 4, 2011-12 ,pp. : 290-297

Bentham Science Publishers

Access to resources Recommend Favorite